Mohamed Rahmani, Ph.D^1*, Mandy Mayo Aust^1*, Elisa Hawkins^1*, Rebecca E Parker^1*, Leonid Reshko^1*, Masey Ross, M.D^1*, Maciej Kmieciak, Ph.D^1*, Kathryn Ann Rizzo, DO, PhD^1*, Catherine I Dumur, Ph.D^1*, Andrea Ferreira-Gonzalez, Ph.D^1* and Steven Grant, M.D.²

¹Virginia Commonwealth University, Massey Cancer Center, Richmond, VA
²Division of Hematology/Oncology, Department of Medicine and Institute of Molecular Medicine, Virginia Commonwealth University, Massey Cancer Center, Richmond, VA

Christina Krupka^1,2*, Thomas Köhnke, MD^1,2*, Peter Kufer^3*, Roman Kischel^3*, Felix S. Lichtenegger^1,2*, Franziska Brauneck^1,2*, Stefan Rohling^1,2*, Torben Altmann^1,2*, Wolfgang Hiddemann, MD, PhD^4* and Marion S. Subklewe, MD^1,2

¹Department of Internal Medicine III, Klinikum der Universität München, Munich, Germany
²Clinical Cooperation Group Immunotherapy, Helmholtz Zentrum München, Munich, Germany
³AMGEN Research (Munich) GmbH, Munich, Germany
⁴Department of Internal Medicine III, Ludwig-Maximilians University of Munich, Munich, Germany

Jiangying Liu, ph.D^*, Hong-Hu Zhu^*, Hao Jiang^*, Qian Jiang^* and Xiao Jun Huang, M.D.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China

Michiko Ichii, MD, PhD^1*, Motohiko Murase, MSc^2*, Kensuke Komatsu, PhD^2*, Motoki Saito, PhD^2*, Jun Toda, MD^3*, Kenji Oritani, MD, PhD^1*, Hiroyuki Iwamura, PhD^4* and Yuzuru Kanakura, MD, PhD¹

¹Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan
²FUJIFILM Corporation, Kanagawa, Japan
³Department of Hematology & Oncology, Osaka University Graduate School of Medicine, Suita, Japan
⁴FUJIFILM Corporation, Tokyo, Japan

Bing Z Carter¹, Steven M. Kornblau, MD¹, Po Yee Mak, MPhil^2*, Hui Yang, MD, PhD³, Yihua Qiu, MD^1*, Xuejie Jiang^1*, Kevin Coombes, PhD^4*, Nianxiang Zhang^5*, Guillermo Garcia-Manero, MD⁶ and Michael Andreeff, M.D., Ph.D.⁷

¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
²Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³Section of Myelodysplastic Syndromes, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁴Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH
⁵Life Technologies Corporation, Carlsbad, CA
⁶Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX
⁷Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston

Isabelle Laverdiere, B.Pharm, PhD^1*, Andrea L. Neumann, BSc^1*, Meaghan Boileau, BSc^1*, Heather Duncan, MSc^1*, Sara Chisling^1*, Amanda Mithchell, PhD^2*, Stanley W.K. Ng, MSc^3*, Jean C.Y. Wang, MD PhD², Mark D. Minden, MD, PhD², John E. Dick, PhD⁴ and Kolja Eppert, PhD¹

¹Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
³Department of Chemical Engineering and Applied Chemistry and Institute of Biomaterials and Biomedical Engineering and The Donnelly Centre, University of Toronto, Toronto, ON, Canada
⁴Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Danny V Jeyaraju^1*, Rose Hurren^1*, Xiaoming Wang^1*, Neil MacLean^1*, Marcela Gronda^1*, Craig T Jordan, PhD², Mark D. Minden, MD, PhD³, Guri Giaever^4* and Aaron D. Schimmer, MD, PhD⁵

¹Princess Margaret Cancer Centre, Toronto, ON, Canada
²Division of Hematology, University of Colorado School of Medicine, Aurora, CO
³Princess Margaret Cancer Centre, University Health Network, Leukemia Program, Division of Medical Oncology and Hematology, Toronto, ON, Canada
⁴2. Department of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
⁵Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Trinayan Kashyap, MS^*, Boris Klebanov, MA, MS^*, Margaret S. Lee, PhD and Yosef Landesman, PhD^*

Karyopharm Therapeutics Inc., Newton, MA

Valentina Salvestrini^1*, Stefania Orecchioni^2*, Francesca Reggiani^2*, Giovanna Talarico^2*, Elisa Orioli^3*, Elena Adinolfi^3*, Francesco Bertolini², Francesco Di Virgilio^3*, Michele Cavo^1*, Roberto Massimo Lemoli, MD⁴ and Antonio Curti, MD, PhD^1*

¹Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
²European Institute of Oncology, Milan, Italy
³Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy
⁴Hematology and Oncology Department, IRCCS AOU San Martino - IST, Genova, Italy

Xuejie Jiang^1,2*, Po Yee Mak, MPhil^3*, Hong Mu, MD, PhD^4*, Weiguo Zhang, M.D., Ph.D.¹, Duncan Mak, BSc, MPhil^3*, Peter Ruvolo, PhD³, Teresa McQueen^3*, Hongsheng Zhou^1,5*, Jorge E. Cortes⁶, Michael Andreeff, M.D., Ph.D.⁷ and Bing Z Carter¹

¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
²Southern Medical University, Nanfang Hospital,Department of Hematology, Guangzhou, China
³Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Section of Molecular Hematology and Therapy, Leukemia Department, UT MD Anderson Cancer Center, Houston, TX
⁵Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
⁶Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston

Paul Brent Ferrell Jr., MD¹, William Senapedis, PhD^2*, Alexander Cook^1*, Erkan Baloglu, PhD^2*, Yosef Landesman, PhD^3*, Jonathan Michael Irish, PhD⁴ and Michael R. Savona, MD¹

¹Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
²Karyopharm Therapeutics, Inc, Newton, MA
³Karyopharm Therapeutics Inc., Newton, MA
⁴Department of Cancer Biology, Vanderbilt University, Nashville, TN

Sivahari Prasad Gorantla, PhD^1*, Detlef Bentrop, Ph.D:^2*, Nikolas Bubnoff, MD^1*, Anna Lena Illert, MD^1*, Robert Zeiser, MD³ and Justus Duyster, MD^4*

¹Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg im Breisgau, Germany
²Institute of Physiology, University of Freiburg, Freiburg, Germany
³Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany
⁴Department of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Freiburg, Germany

Jonathan L. Metts, MD^1*, Heath L. Bradley, M.S.^1*, Neil P. Shah², Reuben Kapur, Ph.D.³, Jack L. Arbiser, M.D., Ph.D.^4* and Kevin D. Bunting, PhD¹

¹Aflac Cancer and Blood Disorders Center, Division of Pediatric Hematology/Oncology, Emory University School of Medicine, Atlanta, GA
²Department of Medicine, University of California at San Francisco, San Francisco, CA
³Indiana University School of Medicine, Indianapolis, IN
⁴Department of Dermatology, Emory University School of Medicine, Atlanta, GA

James M Bogenberger, PhD¹, Nanna Hansen, M.S.^2*, Devora Delman, B.S.^2*, Ruben A. Mesa³ and Raoul Tibes, MD⁴

¹Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ
²Mayo Clinic Arizona, Scottsdale, AZ
³Mayo Clinic, Scottsdale, AZ
⁴Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ

Katelyn Melgar¹, MacKenzie Walker^2*, Jian-kang Jiang, PhD^2*, Kelli Wilson, PhD^2*, James C. Mulloy, PhD¹, Craig J Thomas, PhD^2* and Daniel T Starczynowski, PhD^1,3

¹Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
²National Center for Advancing Translational Sciences, National Institute of Health, Bethesda, MD
³Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH

Fanyi Meng^1,2, Xiaodong Li^1*, Bingjie Ding^1*, Kaikai Huang^1*, Qiuhua Zhu^1*, Fang Chen^1* and Yufeng Zhu^3*

¹Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
²Hematopathy diagnosis and therapy center, Kanghua Hospital, Dongguan, China
³Nanfang Hospital, Southern Medical University, Guangzhou, China

Yoko Tabe, MD, PhD^1,2, Shinichi Yamamoto, PhD^3*, Mika Kikkawa, PhD^4*, Hikari Taka, PhD^4*, Kaoru Mogushi, PhD^5*, Hiromichi Mastushita, MD, PhD^6*, Takashi Miida, MD.PhD^7*, Michael Andreeff, MD, PhD⁸, Paul A Spagnuolo, Ph.D.⁹ and Marina Konopleva, MD, PhD¹⁰

¹Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston
²Department of Clinical Laboratory Medicine, Juntendo Univerisity School of Medicine, Tokyo, Japan
³Department of Clinical Laboratory Medicine, Juntendo University, Tokyo, Japan
⁴Laboratory of Proteomics and Biomolecular Science, BioMedical Research Center, Tokyo, Japan
⁵Center for Genomic and Regenerative Medicine, , Juntendo University Graduate School of Medicine, Tokyo, Japan
⁶Department of Laboratory Medicine, Tokai University School of Medicine, Tokyo, Japan
⁷Department of Clinical Laboratory Medicine, Juntendo University School of Medicine, Tokyo, Japan
⁸Section of Molecular Hematology and Therapy, Leukemia Department, UT MD Anderson Cancer Center, Houston, TX
⁹School of Pharmacy, University of Waterloo, Waterloo, ON, Canada
¹⁰Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Seiichi Okabe, MD, PhD^*, Tetsuzo Tauchi, M.D, Ph.D^*, Yuko Tanaka, M.D, Ph.D^*, Juri Sakuta, MD, PhD^* and Kazuma Ohyashiki, MD, PhD

Department of Hematology, Tokyo Medical University, Tokyo, Japan

Pilar De La Puente, PhD¹, Ellen Weisberg, MD^2*, Atsushi Nonami, MD/PhD², Micah John Luderer, BS, MS¹, Richard M. Stone, MD³, Junia V. Melo, MD, PhD⁴, James D Griffin, MD² and Abdel Kareem Azab, BPharm, PhD¹

¹Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis, MO
²Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³Dana-Farber Cancer Institute, Boston, MA
⁴Haematology, SA Pathology and Centre for Cancer Biology, Adelaide, Australia

John Carl Panetta^1*, Sharyn D Baker, PharmD, PhD², Hagop M. Kantarjian, MD³, Clinton Stewart, Pharm.D.^4*, Blake Pond, MS^5*, Meghan Macaraeg, BS^6*, Tolu Makinde, PhD^7*, Sheetal Vali, PhD^7*, Naval Daver, MD³, Abhijit Ramachandran, MS^8*, Robert Collins, MD⁹ and Jorge E. Cortes, MD¹⁰

¹St. Jude Childrens Research Hospital, Memphis, TN
²Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
³Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
⁵Clinical Research Manager, University of Texas Southwestern Medical Center, Dallas, TX
⁶AROG Pharmaceuticals, Dallas, TX
⁷AROG Pharmaceuticals, Dallas
⁸Clinical Operations, AROG Pharmaceuticals, Dallas, TX
⁹University of Texas Southwestern Medical Center, Dallas, TX
¹⁰Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX